Iovance Biotherapeutics
IOVA
IOVA
126 hedge funds and large institutions have $1.07B invested in Iovance Biotherapeutics in 2018 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 34 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
3% more funds holding
Funds holding: 122 → 126 (+4)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
19% less capital invested
Capital invested by funds: $1.31B → $1.07B (-$247M)
Holders
126
Holding in Top 10
8
Calls
$4.65M
Puts
$1.96M
Top Buyers
1 | +$41.4M | |
2 | +$21.2M | |
3 | +$19.8M | |
4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$10.6M |
5 |
Allianz Asset Management
Munich,
Germany
|
+$6.79M |
Top Sellers
1 | -$54.2M | |
2 | -$14.6M | |
3 | -$8.19M | |
4 |
QF
QVT Financial
New York
|
-$7.56M |
5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$5.38M |